Some studies have reported the clinical and pathological characteristics of breast cancer patients harboring HER2 mutations and/or HER2 fusions, whereas our study mainly explored the treatment pattern and clinical outcomes of various HER2 genomic subtype among these patients. This evidence concerns the gene ERBB2 and breast cancer.